Organon’s VTAMA® (Tapinarof) Cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
Organon announced that its steroid‑free VTAMA® (tapinarof) 1% cream received a strong, evidence‑based recommendation in the American Academy of Dermatology’s 2026 pediatric atopic dermatitis (AD) guidelines. The AAD highlighted VTAMA as the only topical treatment with high‑certainty evidence that is indicated for children aged two and older across all disease severities. The recommendation follows FDA approval for pediatric AD in December 2024 and is backed by the Phase 3 ADORING 1 and 2 trials. AD affects roughly 10 million U.S. children, making this endorsement a major therapeutic milestone.
Elucid Announces Commercial Availability of Lesion Inspection Tool for Plaque-IQ™
Elucid announced the commercial launch of a Lesion Inspection Tool within its Plaque‑IQ software, enabling physicians to quantify plaque composition at the individual lesion level in coronary and carotid arteries. The tool provides quantitative data on high‑risk features such as...
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Precision BioSciences received Clinical Trial Application approval to add sites in France and Romania to its global ELIMINATE‑B study of PBGENE‑HBV, an in‑vivo gene‑editing therapy for chronic hepatitis B. The expansion joins existing locations in the United Kingdom, Moldova, New Zealand, Hong Kong...
Global E·dentity™ Expands Landmark CRADA with DHS & TSA, Powered by President Trump’s Visionary Leadership to Secure America’s National Identity...
Global e·dentity™ Inc., a service‑disabled veteran‑owned firm, announced an amendment (AM01) to its CRADA with DHS and TSA that adds a new Personally Identifiable Information phase focused on privacy‑first biometric digital ID development. The amendment extends the partnership, enabling the...
HYROX and Amazfit Strengthen Alliance With Global Three-Year Partnership
Amazfit, the wearable brand of Zepp Health, announced a three‑year global partnership with HYROX, expanding a prior regional collaboration. The deal adds smart rings, glasses, cameras, and straps to HYROX’s athlete toolkit, alongside dedicated training modes and data integrations. HYROX...
Amadeus Travel Dreams 2026: How AI, Mental Wellbeing, and Sustainability Are Redefining Travel Value
Amadeus' Travel Dreams 2026 study of 6,000 travelers shows mental wellbeing now drives travel choices, with 41% seeking a calmer nervous system. Hotels can unlock up to $1 million extra annual revenue per 150‑room property by retailing six high‑demand attributes such as...
Atelerix Forms Strategic Partnership With JH Health Ltd to Expand Non-Cryogenic Cell Preservation Capabilities in the Middle East
Atelerix, a UK biotech, has signed a strategic partnership with Saudi Arabia’s JH Health Ltd, granting JH Health exclusive rights to distribute Atelerix’s non‑cryogenic hydrogel cell‑preservation solutions across the Middle East. The deal includes funding for high‑volume local manufacturing, regulatory...
Leukogene Therapeutics Announces Two Presentations at the AACR Annual Meeting 2026 Highlighting MHC Class II-Engager Immunotherapies
Leukogene Therapeutics announced two poster presentations at the 2026 AACR Annual Meeting in San Diego, showcasing its MHC class II‑engager immunotherapy candidates for acute myeloid leukemia and pancreatic cancer. The posters will be displayed during the Immunology session on bi- and...
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Who...
Daiichi Sankyo and Merck have received FDA acceptance and Priority Review for the Biologics License Application of ifinatamab deruxtecan, a first‑in‑class B7‑H3‑directed antibody‑drug conjugate, targeting adult patients with extensive‑stage small cell lung cancer (ES‑SCLC) who progressed after platinum chemotherapy. The...
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
Personalis will showcase its ultrasensitive NeXT Personal ctDNA assay at the AAC 2026 meeting, including an oral presentation on neoadjuvant pembrolizumab in high‑risk colorectal cancer. The company will also debut Real‑Time Variant Tracker, a new MRD test option that longitudinally monitors therapy‑resistance...
Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology
Almirall, a global medical dermatology company, has expanded its partnership with the Barcelona Supercomputing Center (BSC) under the BSC Connects program. The new framework, running through 2026, gives Almirall access to BSC’s AI and high‑performance computing resources, including the MareNostrum 5...
Trinity Launches InsightsEDGE™ | Digital Twins — Generative AI Unlocks Always-On Intelligence for Life Sciences Commercial Teams
Trinity announced the general availability of InsightsEDGE | Digital Twins, an AI‑powered platform that creates interactive virtual replicas of healthcare professionals, patients, and payers. The solution leverages Trinity’s 30‑year research pedigree and its proprietary Weave data fabric to continuously ingest claims, EMR,...
Corcept Presents Complete Data From Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus...
Corcept Therapeutics presented final overall survival results from the phase 3 ROSELLA trial, showing that Lifyorli™ (relacorilant) combined with nab‑paclitaxel cuts the risk of death by 35 percent and adds 4.1 months to median survival versus chemotherapy alone. The regimen met both overall...
Prothena Announces Leadership Team Updates
Prothena Corp. announced two senior leadership promotions. Annie Kingston, previously VP of Corporate Strategy, is now Chief Strategy Officer, responsible for growth strategy and the CYTOPE® platform. Michael Isaacs, who has been Deputy General Counsel since 2020, will step into...
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
NeuroPace, the maker of the RNS System for drug‑resistant epilepsy, announced that its executive team will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. The session will be streamed live and a replay will be available...
